WuXi PharmaTech (NYSE: WX) Fills Three Senior Level Positions
Aug 13, 2007
August 13th, 2007 – Shanghai, China – WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today the addition of three key senior level positions. These positions include Executive Vice President of Operations, Vice President of Toxicology and Vice President of Finance.
Mr. Edward Hu will serve as WuXi PharmaTech's Executive Vice President of Operations, reporting directly to Dr. Ge Li, Chairman and Chief Executive Officer of the company. Mr. Hu brings an extensive experience in operations and financial management. Before his appointment with WuXi PharmaTech, Mr. Hu was the Senior Vice President and Chief Operating Officer of Tanox, Inc. (NASDAQ listed company) where he managed operations, finance, IT, project management and strategic planning. Tanox was recently acquired by Genentech, Inc.. In addition to his experience with Tanox, Inc., Mr. Hu has held management positions at Biogen Idec and Merck. Mr. Hu received his MBA and MS in Chemistry from Carnegie Mellon University, Pittsburgh, Pennsylvania.
Dr. Victor H. Chen will serve as Vice President and Head of Toxicology, SuZhou PharmaTech, reporting directly to Dr. Ge Li, Chairman and Chief Executive Officer of the company. Dr. Chen will work closely with Dr. Lijie Fu, Head of Operation, SuZhou PharmaTech to further enhance WuXi's capability and capacity in Toxicology services. Prior to joining WuXi PharmaTech, Dr. Chen held the director position of Toxicology for ImClone Systems Inc. (NASDAQ: IMCL). In addition, Dr. Chen previously held positions in Pfizer and Bristol-Myers Squibb as well as University of Hawaii. Dr. Chen earned his Ph.D. in Environmental Toxicology from the University of California, Riverside and is a Diplomate of American Board of Toxicology.
Reporting to Mr. Benson Tsang, Chief Financial Officer of the company, Christine Lu-Wong, WuXi PharmaTech's newly appointed VP of Finance, has years of experience with "Big Four" in auditing, finance and accounting. She held various finance positions at multi-national companies such as Hewlett-Packard and Sun Microsystems. Prior to joining WuXi PharmaTech, she consulted many companies in San Jose, California including Google and Altera Corporation. Ms. Lu-Wong received her MBA in Accounting from Golden Gate University, California, and is a U.S. Certified Public Accountant.
"I am delighted to welcome Ed, Victor and Christine to our senior management team. Strong execution and relentless focus on delivering quality services have been critical in our success in providing high quality services and expanding service offerings to our clients. As we continue to strengthen and broaden our service portfolio, we must further improve our operation at all levels. Development of significant preclinical and biology capabilities and further strengthening our financial management and internal control system are our priorities. I am very confident that by leveraging our past operation experiences and success in chemistry services these three executives will help augment our service capability and capacity to create more values for our customers and shareholders", commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
About WuXi PharmaTech (Cayman) Inc.
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: www.wuxiapptec.com.